Compare IQV & PUK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | PUK |
|---|---|---|
| Founded | 1982 | 1848 |
| Country | United States | Hong Kong |
| Employees | 93000 | 15338 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1B | 36.2B |
| IPO Year | 2013 | N/A |
| Metric | IQV | PUK |
|---|---|---|
| Price | $247.64 | $29.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $227.13 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 799.4K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | ★ 1.68% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $9,739,000,000.00 | N/A |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.89 | $8.92 |
| P/E Ratio | $151.84 | ★ $23.76 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $24.61 |
| 52 Week High | $247.72 | $34.03 |
| Indicator | IQV | PUK |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 57.96 |
| Support Level | $159.91 | $28.97 |
| Resistance Level | N/A | $30.04 |
| Average True Range (ATR) | 6.70 | 0.40 |
| MACD | 3.10 | 0.10 |
| Stochastic Oscillator | 92.37 | 49.79 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Originally established in 1848 as the Prudential Mutual Assurance, Investment, and Loan Association, Prudential has changed a lot since. Set up to sell life insurance and loans to the middle class, the company subsequently diversified into Europe and then North America with the purchase of Jackson National Life around 1985. During its time as owner of Jackson, Prudential focused on building a simple chassis-style product portfolio that allowed customers to choose from a variety of add-ons. The company also became renowned for its focus on building the internal capabilities required to support its strong product offerings, including compelling technology and a large well-trained wholesale salesforce.